Geron Corp. buy melinda
Start price
03.09.12
/
50%
€2.25
Target price
04.03.13
€2.80
Performance (%)
-51.11%
End price
04.03.13
€1.10
Summary
This prediction ended on 04.03.13 with a price of €1.10. The BUY prediction by melinda for Geron Corp. performed very badly with a performance of -51.11%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | 17.446% | 17.446% | 14.922% | -23.759% |
| iShares Core DAX® | 4.852% | -4.418% | 13.097% | 46.139% |
| iShares Nasdaq 100 | 3.999% | -3.283% | 31.335% | 76.067% |
| iShares Nikkei 225® | 4.221% | -6.223% | 44.472% | 47.139% |
| iShares S&P 500 | 3.324% | -3.174% | 24.360% | 57.683% |
Comments by melinda for this prediction
In the thread Geron Corp. diskutieren
pharma
Geron Corp ist ein biopharmazeutisches Unternehmen, das therapeutische Klasse für Krebs entwickelt (Brust, Lunge)
(Laufzeit überschritten)